Merck KGaA (MRK) Earnings Call Transcript & Summary

November 12, 2020

Deutsche Boerse Xetra DE Health Care Pharmaceuticals earnings 93 min

Earnings Call Speaker Segments

Constantin Fest

executive
#1

Thanks so much, Lauren. Hello, everyone, and a very warm welcome to this call covering Merck's Q3 2020 results. I'm Constantin Fest, Head of Investor Relations, and I'm delighted that our Group CFO, Marcus Kuhnert, is joining me here today. I'd also like to point out that joining us for the Q&A portion of this call is Chris Ross, whom you know from the Capital Markets Day, our Interim Sector Head of Life Science. Also available to take your questions is Darren Verlenden, whom you know from the Process Solutions deep dive sessions at the Capital Market Day, our Head of Bioprocessing, and I'd encourage you to direct any life science or process solutions-related questions to Chris and Darren. And joining this call as well, as you may have noticed, since we have 3 slides on sustainability in this deck, is Mr. Herwig Buchholz, our Head of Group Corporate Sustainability. He's also here for any questions related to sustainability, so please do not hesitate to take the opportunity and ask Herwig. With that said, we'd now like to guide you, as always, through the key slides of this presentation and then answer all your questions during the Q&A that follows. With that, I'd like to turn things over and hand over to Marcus to kick off this presentation. Marcus?

Marcus Kuhnert

executive
#2

Thank you, Constantin, and greetings to everyone joining us — welcome to the Q3 earnings call. I'm looking at Slide #5, which covers the highlights. Overall, the third quarter was very strong and provides yet another proof point that our strategy is being executed successfully. Group sales organically increased 7.2%, while EBITDA surged 52.6%. As you know, earnings received a substantial boost from the Biogen provision release. However, even without that item, organic EBITDA pre rose a remarkably strong 19.8% despite difficult comparables; we also experienced FX headwinds during Q3 — which was likewise the final full quarter of consolidation benefits from Versum. As a result, sales growth as reported was 2.5 percentage points higher than our organic result, and reported EBITDA pre growth matched that figure. In Q3, COVID-19's overall impact was approximately neutral; in fact, we experienced a strong rebound in a number of franchises and growing tailwinds in others. Owing to our effective crisis management, we continue to handle this pandemic's difficulties very well and continue adjusting business processes to fit; this also means that in numerous cases, the boundary separating COVID-19 effects from underlying performance is growing ever less distinct. However, be assured that we will stay as transparent as we can. Because of how well we performed across the first nine months, we're lifting our full-year earnings outlook. Specifically, net sales should now land between EUR 17.1 billion and EUR 17.5 billion, EBITDA pre between EUR 5.05 billion and EUR 5.25 billion, and EPS pre between EUR 6.50 and EUR 6.80. We're also excited to unveil our new sustainability strategy today, and I'll cover that in more detail shortly. Let's now turn to Slide 6, where you'll see how each business sector did in Q3. Turning to organic sales performance, Life Science delivered its strongest quarter ever, with Q3 growth running at over double the pace seen in H1, while Healthcare came back into positive territory following its second-quarter decline, and momentum in Performance Materials picked up noticeably as well. Viewed through the lens we shared at our recent Capital Markets Day, organic growth this quarter came mainly from what we call the big 3 — Healthcare pipeline, Process Solutions and Semiconductor Solutions — with the remainder of the business roughly flat. We faced notable currency pressures — a negative 4% impact on group sales — but gains from the Versum portfolio more than made up for it, bringing total group net sales to EUR 4.5 billion, a rise of 9.7%. On Healthcare, I'd point out that the core business bounced back strongly and came in nearly level with the prior year in Q3, while Mavenclad and Bavencio delivered striking double-digit increases. Over in Life Science, Process Solutions reached an all-time record, posting 27% organic growth, and Research Solutions rebounded markedly following a varied Q2. Applied Solutions likewise showed strengthening momentum. In Performance Materials, Semiconductor Solutions continued its solid organic gains, and the declines in Display and Surface were substantially milder than what we saw in Q2. Turning to earnings, group EBITDA pre reached EUR 1.7 billion, a margin of 38.2% that stands out as exceptionally strong. Yet even if you strip out the EUR 365 million provision release, the margin still climbed 260 basis points to 30%, which shows strong top line growth along with our sustained attention to costs; please also keep in mind that nonrecurring income in Healthcare ran roughly EUR 70 million higher a year ago, partly offset by reduced travel expenses this year, but that still points to an underlying margin expansion beyond 300 basis points; let's move to Slide 7 for some remarks on how sales developed by region. All 3 of our main regions — Asia Pacific, North America and Europe — went back to organic growth in Q3, which reflects the fading of negative COVID-19 effects combined with effective crisis management; across each of the 3 regions, Life Science delivered mid- to high-teens organic growth and Healthcare added positively, thereby more than compensating for organic declines in Performance Materials. Latin America likewise swung positive following its Q2 dip, whereas Middle East and Africa remains negative amid the pandemic's delayed impact. So let's turn now to a closer look at our financial performance and the key developments of Q3. I'm on Slide 9 now, which gives an overview of our headline figures. To repeat what I mentioned before, the release of the Biogen provision provided a sizable lift to earnings. If you strip that out, what remains is still a P&L with attractive leverage, where 10% growth at the top line translated into 20% and 27% growth in EBITDA pre and EPS pre, respectively. I've also pointed out previously that the underlying earnings performance was actually even better, because of sizable swings in nonrecurring income within Healthcare. To be specific, last year's Q3 included roughly EUR 80 million in total, consisting of about EUR 50 million of deferred income from Pfizer and around EUR 30 million of deferred income from GSK. This year's Q3 included only a high single-digit million euro amount, specifically deferred income from GSK. Having said that, we're updating our full-year forecast for deferred income from GSK to roughly EUR 70 million, reduced from the prior figure of about EUR 100 million, which means we anticipate nearly EUR 20 million in Q4. As a general rule, kindly keep in mind that this figure may fluctuate based on cost evolution in the program and on achievement of development milestones. This is just — nothing new here, merely a reminder. We also reaffirm our full-year guidance for up to a mid double-digit million euro amount from active portfolio management. Q3 had no bookings, yet we’re still well positioned to hit the full-year target, thanks to the recently announced out-licensing of M6495, which will, for example, provide support in Q4. Operating cash flow, meanwhile, came in strong at almost EUR 1.2 billion and contributed to cutting net debt by roughly EUR 300 million versus year-end 2019. Keep in mind as well that net debt would be an extra EUR 500 million lower after accounting for the short-term placement of surplus cash we executed during Q3. Let’s now take a moment to go over the as-reported figures on Slide 10. EBITDA pre increased by EUR 589 million, while reported EBIT climbed EUR 558 million. That gap is driven chiefly by greater D&A, which was partly offset on one side by reduced amortization of intangibles and on the other side by increased adjustments. The financial result declined, mostly reflecting smaller LTIP provisions and reduced interest costs. The effective tax rate landed inside the 24% to 26% guidance band, so reported earnings per share reached EUR 1.85, versus EUR 0.79 in Q3 of last year; having covered that, let's turn to our sector review, beginning with Healthcare on Slide #11. Healthcare delivered a solid quarter, posting 3.2% organic sales growth, as a minus 1.4% contraction in the core business was more than compensated for by robust double-digit expansion of our new products, notably Mavenclad and Bavencio. COVID-19 headwinds were considerably milder than in Q2, which shows most clearly in Fertility's strong rebound and Mavenclad's renewed acceleration. All in all, our ongoing crisis management keeps paying off.

Marcus Kuhnert

executive
#3

Even so, a few headwinds persist in certain areas—for instance, Fertility in Asia Pacific and the dynamic MS market stayed muted. Our best estimate, therefore, is that COVID-19 trimmed organic sales growth by 2 to 3 percentage points during the quarter. Healthcare EBITDA pre jumped 94% organically, or 20% excluding the Biogen provision release, and that came despite the lower nonrecurring income versus last year mentioned earlier, which was partly offset by a meaningful cost benefit from fewer face-to-face activities given the pandemic. Earnings growth also got support from solid top line performance and rigorous underlying cost control. We're actually stepping up our push for profitable growth even more, and we've earmarked a provision of roughly EUR 100 million, which will be recorded under adjustments in Q4. Coming from a position of strength, that sum will be deployed over the next several quarters to keep optimizing our organizational structures, in line with how we're executing the earnings phase of our strategic agenda for Healthcare as a global specialty innovator. Finally, in light of our strong 9-month performance, we're lifting our Healthcare guidance for the full year: organic sales growth is now projected at 2% to 3%, and organic EBITDA pre growth at 6% to 8%, or 25% to 27% if you factor in the Biogen provision release. Regarding Q4, that outlook points to sales and EBITDA pre that are flat to modestly higher, and you should view that against tougher comparables plus the early impact of China's third volume-based procurement round; moving on, let's turn to Slide 12 to go through Life Science. Life Science had a genuinely exceptional quarter, posting organic sales growth of 15.6%, which is over double the H1 pace and comfortably above the midterm ambition we upgraded not long ago. COVID-related headwinds in certain areas began easing as anticipated, while tailwinds elsewhere grew, producing a sizable net benefit that accounts for roughly 40% to 50% of our Q3 growth in Life Science, clearly. Each of our three major regions — North America, Europe, and APAC — posted faster organic growth, reaching the mid- to high-teens range. In much the same way, we observed notable acceleration throughout most customer segments. Pharma and biotech, along with diagnostics and testing, stood out as especially strong. Industrial and academia are still affected, though academia bounced back sharply after its Q2 decline. Looking at the portfolio, Process Solutions was the standout, with organic growth climbing even faster to a striking 26.5%, primarily fueled by bioprocessing and aided by a sizable lift from COVID-related demand — I'll say more about that shortly. Research Solutions experienced a dramatic turnaround, going from its weakest quarter to its strongest ever in organic growth terms. So that's a move from negative 7.1% in Q2 to positive 9.5% in Q3. Every business line added to the growth, and several factors were driving that, among them catch-up and certain pull-in effects tied to COVID-19, along with some fundamental improvement. Applied Solutions also accelerated, although the gain was more modest, with organic growth of 3.7% versus a stable H1. Almost all business lines improved, but results remained mixed across customer segments, as we mentioned before, and overall COVID-19's impact was still slightly negative. Pre-EBITDA came in at a robust EUR 630 million. That reflects 25% organic growth, with the margin up 200 basis points to a record 33%. The main drivers were operating leverage, favorable pricing, disciplined cost management, and finally a supportive product mix. As you may remember, on the Q2 call we noted that, on average, the additional demand related to COVID-19 comes with higher margins and produces a positive mix effect. With such a strong 9-month performance, we are raising our full-year guidance: we now expect organic sales growth of 9% to 10% and EBITDA pre growth of 13% to 15%. Regarding Q4, please bear in mind this implies somewhat softer margin growth than Q3; that is largely because of tough comps in Process Solutions plus the catch up and pull in effect in Research mentioned earlier. Before we turn to Performance Materials, let's examine more closely what COVID-19 means for Life Science on Slide #16. In August, we showed you the so-called 2020 heat map, demonstrating that differing factors are at play across business units and customer segments. Our conclusion was that downside would in fact fade once lockdowns are lifted, whereas certain upsides would persist. Q3 already offers strong evidence of that, since COVID-19's net effect became significantly positive. Process Solutions especially enjoys major tailwinds from heightened demand out of portfolios centered on COVID-19 therapies and vaccines. Roughly half of Process growth this quarter comes from COVID-19-related business, and order intake has accelerated further to above 50% across the 9-month period. Still, please note lead times have stretched markedly. Furthermore, many customers of ours working on COVID-19 topics are producing at risk, and different products carry different requirements. So although visibility is good heading into the coming couple of quarters and we are making meaningful headway on capacity expansions, the possible longer-term upside stays hard to forecast. Lastly, let me briefly address Research and Applied. Both moved in a positive direction during Q3, chiefly thanks to improving trends in academia. Both still face headwinds as well as tailwinds tied to COVID-19. But in contrast to Process Solutions, these are generally more balanced, at least across a couple of quarters. To sum up, Life Science's outlook remains strong. Underlying demand is robust, and though longer-term prediction stays difficult, net upsides from COVID-19 are beginning to visibly materialize. I'm certain you'll have further questions about this, and Chris, Darren and myself look forward to discussing them with you later. Having said that, let's turn to the Performance Materials review on Slide #14. On the whole, conditions in PM are still mixed; even so, momentum has picked up considerably versus Q2. Reported sales growth came in strong at more than 40% for Q3, mirroring moderate FX headwinds and, clearly, a sizable portfolio effect from Versum as well. On an organic basis, sales fell minus 5.4%, a far better result than the minus 13.7% recorded in Q2. Roughly half of that gain stemmed from COVID-19 headwinds easing, while the remainder is attributable to normalizing comps in liquid crystals plus better underlying performance, helped along by rigorous cost management. Semiconductor Solutions, the biggest business unit within Performance Materials, posted yet another strong quarter, with organic growth of 8%; and though you'll have noticed this sits slightly under the growth seen in the previous 2 quarters, it remains a strong quarter and lands toward the high end of our midterm guidance. Note as well that legacy Versum's growth matched this, and integration keeps running smoothly, with synergies arriving even sooner. That means we now anticipate roughly EUR 30 million in cost synergies being realized in 2020.

Marcus Kuhnert

executive
#4

Organic sales for Display Solutions fell nearly 10% as liquid crystal comps normalized, though COVID-19 headwinds eased and underlying performance stayed solid. At Surface Solutions, organic sales dropped 12.6%, and as with Display Solutions, that decline was under half the Q2 rate, largely because COVID-19's impact was less severe. Turning to earnings, reported EBITDA pre rose 43.3%, since the Versum portfolio effect more than outweighed a modest organic decrease and currency headwinds. Costs remain tightly controlled, helped by strong execution of our Bright Future transformation program and COVID-19 countermeasures, yielding a steady 30.4% margin. Given the solid 9-month performance, we are modestly raising our full-year guidance for Performance Materials and now anticipate organic sales and EBITDA pre declines of minus 4% to minus 5% and minus 6% to minus 9%, respectively. The Versum portfolio effect in the mid-30s percentage range for both sales and EBITDA pre is confirmed. For Q4, please remember there will be no Versum portfolio effect, and we expect very strong organic growth, also reflecting low comps tied to the change of control, as mentioned on earlier calls. Moving to Slide 15 for a few comments on our balance sheet. As you can see, little has changed versus year-end 2019; cash and cash equivalents remain some EUR 750 million higher, consistent with the end of the prior 2 quarters and reflecting our prudent approach to securing liquidity during this crisis. Our equity ratio stays above 40%, and net debt-to-EBITDA improved from 2.8 at the end of December to 2.3 at the end of September. Let's now examine cash flow more closely on Slide 16. Operating cash flow was strong at EUR 1.17 billion, up EUR 240 million versus Q3 last year. Adjusted for the Biogen provision release, cash conversion as a percent of EBITDA pre improved, mainly due to lower net working capital outflows. Investing cash flow rose significantly, reflecting temporary investments of excess cash, as already noted. CapEx was also higher. And as you may have noticed, we are raising our full-year CapEx guidance by EUR 100 million, mainly due to accelerated spending on growth projects, for example, in Process Solutions. Finally, financing cash flow in Q3 was at a more normal level, while last year included significant effects related to financing the Versum acquisition. With that, let's turn to the guidance, to the outlook. Before detailing our guidance upgrade, let me begin by reflecting on our performance in the context of the COVID-19 pandemic. I'm on Slide 18 now. During our recent Capital Markets Day, we outlined how much progress we've made in becoming a top-tier global science and technology company—spanning both our portfolio and our culture. After a stretch of heavy investment, last year we moved into the growth and expansion stage of our strategic plan, and we committed to you that Merck would represent profitable growth with a high-margin, low-risk profile. 2019 was a strong beginning for this phase. And although we carry plenty of momentum into 2020, the COVID-19 pandemic proved to be a serious test. Obviously, we could not entirely insulate ourselves from what has become the worst worldwide downturn in more than 70 years. Even so, we will still deliver profitable growth in this turbulent 2020, and today we confidently restate that commitment. With a clear set of priorities guiding us—as this chart shows—we have successfully navigated a range of challenges while at the same time spotting and seizing new opportunities. Consequently, our business performance is robust, and we are well on course to offset the pandemic's effects, even running slightly ahead of plan. I'm now on Slide 19, where I'll briefly recap the main earnings drivers for 2020. As you'll see, little has changed relative to the version we presented in August. The one noteworthy addition is a provision release of EUR 365 million tied to the patent litigation with Biogen. So let's move directly to the group guidance on Slide 20. As I mentioned earlier, we now anticipate group net sales between EUR 17.1 billion and EUR 17.5 billion, EBITDA pre between EUR 5.05 billion and EUR 5.25 billion, and earnings per share pre between EUR 6.50 and EUR 6.80. We've tightened the group net sales guidance range by EUR 400 million, while keeping the midpoint the same, since improved organic growth of 4% to 5% is offset by larger FX headwinds, now estimated at minus 2% to minus 3% versus 0 to minus 2% previously. For EBITDA pre, we've narrowed the range by EUR 200 million and simultaneously raised the midpoint by EUR 500 million. Of that upgrade, EUR 365 million comes from the Biogen provision release, with the rest reflecting stronger organic growth of 6% to 8%, partly offset by larger FX headwinds, now assumed between minus 3% and minus 5% versus minus 2% to minus 4% before; for EPS pre, we've narrowed the range by EUR 0.35 and are lifting the midpoint by roughly EUR 0.70, including about EUR 0.63 from the Biogen provision release. Lastly, please note that the expected portfolio effects from Versum are confirmed as a positive mid-single-digit percentage effect for both net sales and EBITDA pre. Let me also briefly comment on our business sector guidance on Slide #21. While this has been qualitative up to now, we're also giving quantitative targets for each business sector. As you can see, we've slightly raised our organic sales and EBITDA pre assumptions across all 3 businesses, and for Healthcare we've additionally factored in the Biogen provision release. With that, let's turn to Slide 22 for today's special topic, which is the introduction of our new ESG targets. Going forward, growth won't be driven only by the sheer volume of new business, and even today the success of the company is no longer measured solely in financial KPIs. Through our transformation into a leading science and technology company, we've built the mindset needed to successfully link business and societal value. Whether it's displays with low energy consumption or enabling scientists to develop new therapies, technical expertise, innovation power and a sense for unmet needs in the pharmaceutical, life science and electronics space have already led to a number of pioneering products from Merck. Top ratings from leading sustainability platforms such as Sustainalytics or MSCI confirm that we're already on the right path to contributing positively to sustainability. Just 4 weeks ago, the Wall Street Journal ranked us #4 out of the 100 most sustainable companies and #1 in social responsibility.

Marcus Kuhnert

executive
#5

That said, to push things further and stay abreast of how quickly ESG is evolving — both in terms of reputation and from a business standpoint — we chose to embed the ESG focus more firmly across our businesses, R&D and governance. So we came up with 3 new sustainability targets along with 7 focus areas, which align with our particular strength in innovation and will steer key actions as we work toward strengthening what we contribute to sustainability. Our first target factors in how all 3 sectors add to human progress and well-being; by 2030, we will advance human progress for more than 1 billion people through sustainable science and technology from Merck. Our second target captures the need to bring sustainability into our value chain so we can keep developing a range of governance and operational fields amid a shifting environment; that covers, for instance, our culture and values, transparency across our supply chains, and risk and life cycle management. With more than 50,000 employees and more than 50,000 suppliers, this is a massive task with real impact. Our environmental approach is captured in our third target. By 2040, we intend to reach climate neutrality and to cut our resource consumption substantially when it comes to waste and water. Since the new sustainability strategy forms an integrated piece of our overall strategy, we will strengthen in-depth steering of operations, craft tailored KPIs for reporting and mirror all of this in our compensation scheme. So let's move to Slide 24 for a view of what we could contribute to and gain from ESG. The strategic exercise we ran over the past month has deepened our grasp of the 17 Sustainable Development Goals set by the United Nations where our impact can be strongest. As you can see, this slide shows the 5 SDGs most relevant to us. The clearest match is SDG 3: good health and well-being. There, Merck is well positioned to contribute through dedicated products and initiatives in pharma, science and technology. Much the same holds for SDG 9, which we have addressed through our innovation power. For the remaining 3 as well, we see a strong rationale for how they tie to our strengths and targets. Last, we are convinced sustainability can benefit society and business alike. Specifically, we expect our new targets to serve as useful guardrails toward even greater resilience on one side, and on the other side, additional economic growth via new partnerships and business opportunities. With that, let's turn to the final slide, which lays out our ESG road map for the years ahead; we made meaningful progress during 2020 by carrying out an in-depth analysis of our operations and focus areas, the shifting regulatory environment and what our stakeholders need. Building on that, we reassessed our sustainability strategy, which produced our new targets and ambitions as just shared with you. We'll also keep reviewing and refining our targets, since we recognize that the whole ESG area is still very dynamic. Right now we're putting together a solid data platform so we can steer sustainability-related processes better internally. On that foundation, we'll create ESG KPIs for external reporting and fold them into the compensation schemes for both the Executive Board and senior management starting in 2022. We're already pursuing an integrated approach across all businesses and will keep developing strategies to embed ESG fundamentally in R&D, controlling M&A and our supply chain, to give just a couple of examples. Overall, we're confident this will help us make the right calls on dedicated investments and initiatives so we can reach our new targets. Thank you. And with that, we'll open it up to your questions.

Matthew Weston

analyst
#6

Two questions, if I may. First, for Darren, about Process Solutions and that fantastic growth. For several quarters now you've warned us about possible capacity limits on growth in that business, yet you keep delivering incremental accelerating revenue, and the order book is clearly growing. I completely understand Marcus' points about some of your customers now taking risk. But could you please walk us through how much capacity you're currently able to add? And are we getting to growth levels where you'll really run into supply constraints that could curtail your ability to grow going forward? Then my second question, if I can, concerns the M7824 non-small cell lung cancer lung study. I can see there's a lot of detail on Slide 41 and clear commentary that you won't share very much information; but many investors found it very surprising that you continued with the 300-patient trial; so can you give us any color that you can, but most importantly, can you reiterate your confidence that even with only 300 patients and with a PFS and OS endpoint, you are confident that this trial could have registrational potential?

Marcus Kuhnert

executive
#7

Thank you, Matthew. And yes, as you suggested, I would hand the first question directly over to Darren.

Darren Verlenden

executive
#8

Thanks. I appreciate that, Matthew, and I also want to acknowledge how much the Process Solutions business has improved — a 27% increase really is tremendous. That said, as you pointed out, despite the enormous expansion we are experiencing, we do face certain capacity constraints at present. As Marcus also mentioned, our lead times are beginning to lengthen as we move further into this pandemic period. We are lucky enough to have several modalities for addressing the pandemic, including a vaccine candidate, nucleic acid therapies, and monoclonal antibody therapies. So as our lead times have stretched, we have taken a thorough look at both our near-term and long-term planning outlooks. In fact, we have made some considerable investments in capacity for the short term. To date we have put in roughly EUR 30 million — more than EUR 30 million — specifically in our single-use platforms and our filtration platforms, and in growth. So we are examining our order book, we are examining the long-range plans and the short-term implications, and we are investing and speeding things up where necessary so that we can move this demand forward.

Christos Ross

executive
#9

And Matthew, Chris here — let me just add a little to that. I think near term, in Darren's business, Q3 was a really strong performance, as was noted. And output from our manufacturing operations came up a lot in Q3; and we're seeing some steps put in place to give allocation principles to some of our customers, to redensify some of our operations, and also to take advantage of some hiring we've done in many locations, really to raise capacity in the short run. But as Darren said, the investments we're making for the future, especially in filtration and single use, we'll see the benefits from in the first part of 2021.

Marcus Kuhnert

executive
#10

Appreciate it, Chris and Darren. Matthew, on your second question: I realize our recent announcement about stopping enrollment at 300 patients and moving to active, not recruiting status has led to a fair amount of conjecture about how the study might turn out. I'm also aware those readings cover a fairly wide spectrum — everything from quite favorable to quite unfavorable. As you know, we're somewhat constrained; there's only so much we can say on this subject, correct? What I can share is that we've gotten an unambiguous signal from the independent data monitoring committee that futility has been passed. That means the trial goes on. And although it's too early to speculate about the trial's outcome on the basis of enrollment ending at 300 patients, we will nonetheless keep the trial going. Let me restate very plainly that, yes, there is confidence — we wish to restate our confidence that this trial is registrational, or registration relevant. Let me also clear up one further point once more. As a matter of fact, the interim data are not known to us. Those data are blinded to the study sponsors. That means neither we nor GSK know what the interim results are; only the IDMC had that knowledge. They reviewed the interim data, and their decision was solely that futility was passed and that we are proceeding; beyond that, nothing has changed. It is a registration relevant study, and we have — we've passed futility, which I think is a good sign, and we are now carrying on. Yes, with the relevant endpoints, PFS and OS, as we changed, I believe, in March, when we moved to the adaptive trial design.

Matthew Weston

analyst
#11

Could I ask a quick follow-up about the Process Solutions topic? I'm simply trying to get a sense of how much of the supply and revenue booked in Q3 was basically manufactured live, so to speak, versus coming out of inventory? And I realize a lot of what you supply is highly specialized for your customers. So I suppose my question is: if you had to ship the identical amount again as what you shipped in Q3 and Q4, does your manufacturing capability allow for that? Or are we getting to a point where you've been shipping out of inventory, and we'll have to play catch-up as new capacity comes online early next year?

Christos Ross

executive
#12

This is Chris; and I mean I'll build on where Darren started regarding lead times. I think it's key to recognize that our lead times have stretched quite substantially. So the increase in order intake during the current quarter certainly doesn't convert into sales growth a couple of quarters out. So we're seeing a typical lead time in the 2 to 6-month range and orders not usually sitting in the 4 to 6-month range. So we are observing a shift in that landscape; and a heightened degree of advanced order placement is occurring as well with our COVID-19 regular business; so there's an appreciation here of what's happening with the supply constraints, but we are making progress there, and we see that our strong H1 next year. But it becomes a little bit less clear in the second half of the year.

Richard Vosser

analyst
#13

So I'd like to begin with a quick follow-up question about Process Solutions. Thinking specifically about the vaccines, we've clearly had 1 positive vaccine so far, but if the AstraZeneca gene vaccine reaches the market, or one of the others does, could you share some perspective on how we ought to view that as a revenue opportunity for Merck in '21? My second question goes back to TGF beta. Maybe you could explain a little why the milestone income — the upfront milestone income — is being spread out across a longer period of time; what's the reason for that? And given that, how should we think about the amount that's left the book in 2021? Then finally, just on Mavenclad; it looks like the ex North America revenue is roughly EUR 74 million. So perhaps you could give us the fleet of that, or maybe not an exact split, but talk about the revenue coming from returning patients versus new patients in the market outside of North America?

Marcus Kuhnert

executive
#14

Yes. So we start with the life science part. Chris, Darren?

Christos Ross

executive
#15

Yeah, yeah, that sounds fine, Marcus — thanks. So let me begin with what I'd call the good news of the day, which is the BioNTech Pfizer announcement. The clinical results are genuinely very exciting and represent a big step forward here; and we're seeing an expectation that as many as 675 million people will be vaccinated by the end of next year. That's roughly 10% of the global population; so that really is the good news. But other vaccines and other treatments are still needed. We're in a strong position when it comes to COVID-19 developments across mAbs, vaccines, and nucleic acid approaches, and we'll have an important part to play in treatment strategies over the next several years — I'll let Darren go into that in a bit more detail. As we're seeing, a vaccine that works well could of course cut back on the use of mAb cocktail treatments in a prophylactic setting, but those treatments will remain necessary for patients who have severe symptoms. So we still see a solid outcome on that front. Also, the cold chain requirements, along with the cost and the availability of the mRNA vaccine, pose difficulties. So on the whole, we anticipate the market will keep moving forward with a range of modalities and differentiated technologies to address ongoing needs. Darren, I think it might help to add a bit more context here, so I’ll hand it over to you.

Darren Verlenden

executive
#16

Absolutely, Chris, and thanks. If you look back to our Capital Markets Day in September, we mentioned that we were evaluating more than 300 distinct candidates across the pipelines for these therapies, vaccines, and treatments. That's really the advantage of the Process Solutions business — we have an essential role in every one of those therapies, whether that involves services, products, or the CDMO landscape. So it's genuinely encouraging that we're making progress with these therapies for patients and for global health, so to speak. But we do play a major part in all of these candidates as they move forward. And I think when you consider the profile of our business and where we're putting investment — the capacity, including into the R&D landscapes of some of these new mRNA therapies that are reaching the market — we've been investing heavily in our R&D resources and our CDMO footprint so we can capture the full breadth of opportunity that this market offers us today.

Marcus Kuhnert

executive
#17

Alright, Richard, I'll handle the second question about the bintrafusp milestones. To begin, let me give everyone a quick refresher on how the deal is structured. We're talking about a net present value of EUR 3.7 billion. Of that, we've received EUR 300 million as an upfront payment, as you know, and then there's EUR 500 million in potential development milestones, with the remaining EUR 2.9 million being milestone payments tied to approvals and/or hitting commercial thresholds. So that's when products are on the market and we reach certain sales thresholds. I think what's under discussion is the EUR 500 million in development milestones. Let me be clear: so far, no milestone payment has been made. Up to now we've only received the collaboration upfront of EUR 300 million, which, as you know, will flow through deferred income into our P&L over the next 2 to 3 years. One point: no milestone payment yet. It's impossible for us to predict when those milestone payments will come; and let me remind you again, as we already said on our Q2 call, there was one first analysis of interim data earlier this year. Some others will most likely come, but we've never disclosed any kind of comparison between interim data readouts and milestone payments. We've just said that eventually the outcome or data from the lung program as a whole could trigger those development milestones. There's not much more to say, Richard. The second question was about revenue from returning versus new patients for Mavenclad outside the United States; we can't give a specific split, but we can say that new initiations are rebounding after the lowest — the low point in April across all major markets outside the U.S., with very good performance for — sorry, for year 2 return patients. And you can — or we interpret this, and I hope you do too, as a sign of continued confidence in Mavenclad. And also, please remember that there was a general pause of the entire high efficacy market due to COVID-19. That means there were no new initiations and no re-treatment of patients, and this is still a little bit ongoing. So this still hasn't fully recovered; we're now navigating through this, and we can confidently say that the returners are coming back.

Sachin Jain

analyst
#18

If I could, a few things. First, regarding Process Solutions — and forgive me, I might be confusing myself, but let me just get clarity on what you can see regarding lead time and the order book. I think you covered this in the previous question: you have 2 to 4 months of visibility on the order book. So could you talk about how sustainable that is, the existing 50% through the fourth quarter and into next year? When you say you have visibility on the business until 1H, does that mean the order book or delivery of sales, which I would imagine gives you longer visibility than that? Let me get to the other thing I was asking about — your lead time, which I believe you said runs two to six months and has gotten longer. What that suggests is that anything in the 2Q order book is going to be delivered through 4Q. I just want to confirm that's right. My second question is a big-picture one about margins going into '21. On Life Science, can you give any color on how we should think about margin uplift from that accelerated Process Solutions growth versus what you said before? And on Healthcare, is the absolute cost decline this year able to carry on into '21? And then one last question, at a high level, on pipeline. Could you give us some detail on how the pipeline is shaping up, covering both products, and whether that turns positive next year if things stay at current levels? I’m trying to triangulate the EUR 2 billion pipeline target for ’22 against consensus sales of roughly EUR 700 million-ish this year. So would the ’21 pipeline figure land somewhere around the midpoint of those, at about EUR 1.3 billion-ish, or how do you view the phasing of the pipeline across the next 1.5 years, 2 years?

Marcus Kuhnert

executive
#19

Yes. Let’s begin again with the Life Science question, Chris, Darren?

Darren Verlenden

executive
#20

Sure. So Sachin, thanks once more for asking about the order book. As Marcus mentioned during the opening presentation, we are in fact reporting growth in our order book of more than 50%, and that is higher than the guidance we gave in the first half, which was above 40%. What is actually happening is that we are beginning to gain improved visibility and transparency into the orders and their sources, whether they come from base business or are COVID-related. I think you can appreciate the landscape we find ourselves in at present, where some of these customers of ours actually have business in both areas, COVID-19 and non-COVID. So it really comes down to our ability to hold these very intricate discussions with our customers so as to understand where the business originates. And that is genuinely enabling us to sharpen our pencil regarding the order book and what is tied to what, and what we can actually prioritize. I think, as you have heard, we have had an entire prioritization scheme, in which COVID and government-rated orders hold first and foremost priority, moving down the lines as you go through that allocation. So yes. So as lead times begin to extend, as Chris said, we are in this — our average is around 2 to 6 months; and again, it is really tough to say, because the product portfolio is so diverse and differentiated, whether that be filtration, whether that be cell culture media, single-use, each one carries its own nuance, if you will, along with the ability to deliver and the lead times required from there. But we are seeing that lead times are going up from that 2 to 6 standpoint into the 4 to 6-month window. But again, it depends on the product actually that we are delivering and shipping to those customers.

Christos Ross

executive
#21

And I think it's worth remembering that COVID customers are manufacturing at risk, and the odds are very low that every product now in development will secure approval. So we have to watch how that unfolds. That introduces a bit of murkiness there. And different products come with different requirements. We've discussed this before too — for instance, we sell more of our products into the manufacturing of mAbs and vaccines; so some clarity needs to arrive in the second half of the year, but I agree with Darren's comments on the lead times.

Marcus Kuhnert

executive
#22

Alright. Then, Sachin, your second question concerned possible margin improvement in 2021. As you're aware, we won't give you precise guidance today on margins by business sector at the product level. But what I can do is offer a couple of hints and comments. To start, keep in mind that Life Science had a truly standout Q3 2020 — not only in terms of top line momentum but profitability as well, powered heavily by that remarkable top line expansion, powered heavily by the COVID-19 tailwind that remains very strong, which has — or which creates a favorable mix effect I described a few minutes earlier during the presentation, and additionally bolstered by robust favorable pricing effects observed in Q3. Looking at 2021, even if we assume highly bullish conditions, we honestly cannot envision a scenario where organic growth for Life Science would surpass the mid-teens range in the coming year. In our base case, we'd expect growth along the lines of what fiscal year 2020 is showing, and we're still ahead of the midterm guidance we upgraded recently. That carries over to the margin as well — I wouldn't necessarily extend or carry this exceptional 33% further into 2021. Naturally, we hold to our ambition of keeping margins at least stable as we go forward. And obviously, in a market environment this benign, we also see room to push margins higher. But as I mentioned, the 33% is, I'd say, an exceptional level too, one we enjoyed this quarter. Regarding Healthcare, there are a few dynamics at play. On one side, we gained from the COVID-19 situation and the cost effects tied to it. During 2020, roughly — I'd estimate by the close of this year, approximately EUR 150 million. Suppose we distribute that EUR 150 million in proportion to each business sector's sales share, then subtract a modest portion since group functions clearly played a part too — that gives you a sense of the cost benefit, or savings advantage, that our 3 business sectors are presently, so to speak, getting as backing to offset the revenue pressures. We ought to avoid getting overly optimistic about whether every bit of that can hold up in 2021, once business conditions return to something closer to normal. And given, say, the latest developments on vaccines, that scenario isn't entirely far-fetched. My expectation is that we'll travel more — somewhat more travel next year — that we'll make more visits to customers, and that we'll hold other customer events within our businesses as well. While we have no intention of reverting to the cost structure that existed before COVID—that absolutely must not occur under any scenario—we will ultimately need to put some money back into things like impersonal relationships, across many areas and in the widest possible sense. So it's fair to assume that a portion of those savings will extend into 2021, though certainly not the entire amount we managed to capture this year, which was also helped along by the crisis conditions. On the pipeline, that's the last question. I see your point. To reiterate, the key drivers in 2022 will clearly be Mavenclad and Bavencio. We also anticipate contributions from tepotinib and, in time, bintrafusp. At this point I'm unable to offer exact guidance on the pipeline or on new product sales for 2021. That said, given the distance we still need to cover to get to EUR 2 billion, it's fair to assume we'd rather not weight things too heavily toward the back end, since that would leave us carrying substantial risk into 2022. So we will keep pursuing quite aggressive rollout plans, and continue to do so, in order to drive a further strong ramp-up in 2021 as well. Beyond that, there's nothing more I can share.

Peter Verdult

analyst
#23

This is Pete Verdult at Citi. I have two questions, on Life Science and bintra, a bit dull. First, on crystal, Marcus, did I understand correctly that you put your best estimate for Process Solutions growth, once you strip out the COVID benefits, at roughly 13% to 15%? And can you clarify, with respect to inventory management and avoiding stock-outs, that we aren't in that kind of position yet, given the demand surge you're seeing? Then on the bintra markets, I mean, you noted that you're still blinded to the results. So could you explain the basis on which it was decided at that point not to expand the trial? Given the price and the offer as well as the hurdle, it looks like a prudent move. So anything you can tell us on that would be appreciated. And perhaps a last one on bintra. What's the very latest on the next interim, or when do you expect that 037 study to read out?

Christos Ross

executive
#24

I'll start with Life Science, on the Process Solutions side. So yes, organic growth, as we discussed in Q3, was very strong at 26.5%. And here, just to answer your question. The estimated net effect from COVID accounts for roughly 50% of the Q3 growth. So for us this still implies solid base business growth of around 13%. So that's well in line, a little above our midterm guidance for low teens growth. A bit below the growth rates we discussed earlier for COVID, and this is probably because some of the base business was slightly affected by the allocation principles toward COVID.

Marcus Kuhnert

executive
#25

Turning to your first question about bintrafusp, Peter. First, clearly, this choice—for which we have completely enrolled 300 patients, along with a result from the independent data review committee that was handed to us. And once more, the reasoning underpinning that choice isn't visible to us—it hasn't been visible to us. Unfortunately, therefore, I also can't talk through the advantages and disadvantages of it. It was simply something we had to accept once the independent data monitoring committee had gone through the data. They told us, okay, you've cleared futility, which obviously was welcome news, and after that they said, okay, we go forward with 300 patients, right? So, as happens with any other trial, now to the second portion of your question, several interim analyses are planned. And likewise for 037 from now until the study ends in April 2023, which is the primary completion date currently estimated and which will, of course, be event-driven. And again, sorry to say, I hope you understand that we're unable to go into further detail at this moment.

James Quigley

analyst
#26

Quick question on the cost savings. You mentioned a EUR 100 million provision in Q4 to support efficiency gains and that sort of thing. What's the target there — how much could you potentially save in absolute terms, and from a margin standpoint going forward? And second, in Process Solutions, do you have any read on how your customers' inventory looks? Clearly, they're probably going through it pretty quickly. But is anyone ordering extra to build a buffer for later?

Marcus Kuhnert

executive
#27

Yes; regarding your first question, that EUR 100 million — the EUR 100 million funds a group of initiatives we're carrying out in Healthcare to get ourselves ready for what's ahead. And please keep in mind, this is certainly not a case of us putting out a fire; rather, over the years, say, with the original development plans for the pipeline, et cetera, we've come to see that in certain areas, reality has simply unfolded somewhat differently from those original plans. And we believe the time has now come to adapt our structures accordingly. So the program carries very strong organizational or structural elements. Beyond that, we’re tackling culture too—something we see as vital—since our aim is to encourage simplicity, accountability, and execution as the principles that guide us, and to embed that mindset even more deeply across the whole company. We're tackling how work will be done moving forward, and we're also looking at inefficient org structures in several places—go-to-market, R&D, and so on and so forth. So I'd describe this as a major organizational effort that's also cultural, aimed at getting full value from what we've invested in the past and using this initiative as a logical next step within the longer-term transformation of the health care sector and the successful—or completing the successful—transition, or locking in the successful transition now into the earnings phase, which is what we promised you. Could you please repeat your second question again?

James Quigley

analyst
#28

My apologies. So on the second question, do you have any kind of visibility into your customers' inventories within Process Solutions? Clearly, they're going to work through that inventory fairly quickly.

Marcus Kuhnert

executive
#29

Yes. I'd hand this over to Chris and Darren, naturally.

Darren Verlenden

executive
#30

I really can't comment on what our customers are doing with their inventories. That's not something I can address, nor can I speak to their practices. What I can say is that, looking at the orders coming into the Process Solutions business, some customers are placing orders ahead of time — they understand they need to get in the queue so they have the raw materials when they need them, at the right time. So yes, we do see customers planning in advance and planning well ahead; but again, we continue to follow our allocation practices, which are government-rated orders and COVID first, life-saving therapy second, life enhancing therapies third, and then clinical programs in the last spot as we move ahead.

Falko Friedrichs

analyst
#31

Let's start with Bavencio, if we could. Can you walk us through again what drove the uptick in Q3 and what you heard from physicians over the quarter? Second, you mentioned CapEx will be somewhat higher this year. Could you quickly remind us what specifically that spending covers this year? And perhaps give us some sense of next year as well — should we expect an elevated level then too? Third, FX is clearly a huge headwind for so many companies, and for you this year too. I figure it would be useful for each of our models to include some sense of what the downside could look like in 2021 assuming FX rates remain at current levels.

Marcus Kuhnert

executive
#32

Falko, let me take your second question first — regarding the higher Capex, we genuinely have plenty of growth opportunities. You've likely already picked up from our quarterly release and from what Chris and Darren shared that we're now carefully evaluating how durable the COVID-19 tailwind is in Life Science, and identifying the areas where we can invest safely to capture future benefits sustainably. The primary investment we currently have in mind is actually one that supports growth of the Process Solutions business. That shouldn't come as much of a surprise, since it serves the strong demand and expanding markets there; and in fact it includes expansions at two of our U.S. plants, where we'll add capacity, particularly for single-use assemblies and downstream filtration. Beyond that, we're also examining expected capacity against long-range demand across our product portfolio, and we'll put together a prioritized set of expansions to speed up relative to the existing plan. As for the FX headwind topic, judging it is fairly hard at this point in time. I have to be honest that we haven't yet taken an in-depth look at it either, since our planning meetings are still ahead of us. There, we'll then get up to speed on, let's say, how FX is developing in our businesses and in our regions. As things stand right now, it's clear enough that foreign exchange will probably work against us in 2021, though beyond that I'm not able to share much detail yet; turning to Bavencio. You wanted a recap of the third quarter plus some physician feedback gathered during it. Growth has been quite strong. Overall, Bavencio rose 53% compared with the same period a year earlier, and the sequential gain of 41% over the second quarter is rather striking. What that tells us, plainly, is that first-line bladder is driving the bulk of this improvement; the first three months since launch are going remarkably well. Naturally, a word of caution is warranted—3 months post-launch remains quite early. Still, the initial indicators look highly promising and are laying a solid groundwork for 2021. Now let me direct you to Slide #37 for a few—actually, a few additional specifics. Here on this slide, at the right, Bavencio first-line bladder is shown. Robust early launch momentum, and the community-setting uptake confirms how meaningful the overall survival benefit is in this setting. We've observed encouraging data points that Rehan discussed during the September R&D update, and they keep trending favorably. Penetration continues rising, correct? We figure we now hold a 50%—roughly a 50%—share here; and we've likewise maintained growth in the number of accounts ordering Bavencio. On top of that, we hold a leading share of voice exceeding 50%, which is another very supportive factor. So overall, I'd say we've gotten off to a strong start and remain on track to shift the standard of care in the indicated segment.

Daniel Wendorff

analyst
#33

And I have three. Two of them concern Process Solutions. When you mention that several of your Process Solutions customers have begun producing at their own risk, could you give us a sense of what number we're talking about here? Is it a single-digit count of customers, or is it a double-digit count of customers? And then my second question about Process Solutions relates to order intake. Looking at the order intake growth you saw in Q3, how much of that is really driven by COVID-19-related demand? And what is really underlying growth — order growth development? And my last question is for Healthcare. How should we think about the sales development of Glucophage over the next quarter, potentially over the next quarters when considering the situation in China?

Marcus Kuhnert

executive
#34

Yes. We start with Life Science. Over to Chris and Darren.

Darren Verlenden

executive
#35

Okay, Daniel, thanks. And to be clear, when we describe customers as producing at risk, that simply refers to the situation where they're manufacturing in the context of seeking a treatment approval, so to speak. So again, I can't address what the specific split is regarding which of them are producing at risk and which aren't. But to be sure, this does feed into the order intake we're seeing and the growth in the COVID-related area, tied to the notion that many of these customers—whether or not they hold approvals for treatments—are manufacturing, correct? And looking at this, order cancellation is one risk we face, and it could be among the outlier scenarios in that regard. But in case you're wondering or have a view on it, we see limited risk on that front too, since demand is high and there's limited room for orders to be cancelled down the road. And then I believe you also had a question tied to order intake. Could you repeat the order intake question, please?

Daniel Wendorff

analyst
#36

Let's talk about the order intake growth on an underlying basis. So how would that figure have looked for the quarter if we set aside the projects tied to COVID-19?

Christos Ross

executive
#37

Sure, Daniel, I'll handle that question — it's Chris here. As you're aware, the biggest drivers behind the portfolio's growth are the COVID-19 treatments and vaccines. To give you a rough figure, we're currently working on more than 50 vaccines plus over 20 treatment solutions. Now, regarding COVID versus non-COVID, we estimate that roughly 30% of the growth in the order book at present is linked to manufacturing processes specific to COVID-19. Earlier, I believe we reported that figure as 50%. But with the transparency we now have with customers at the level of specific molecule applications, we're examining this far more closely. And as a matter of fact, we're seeing that the base business is holding up quite strongly too. So that's the most recent update.

Marcus Kuhnert

executive
#38

There's one more question on that — please go ahead and open the line. Daniel, you raised the question of the VBP impact on Glucophage. So, first, the initial effect will obviously show up in Q4 2020. It will be moderate, though, and it is — or will be — fully reflected in our guidance, obviously. Second, I'm sure you've already heard this, but to restate it: we have just wrapped up, or finalized, talks with the Shanghai authorities regarding what's called the gradient price cut. As you're aware, the gradient price cut applies to the segment — the public hospital segment — where we continue to have access, meaning it isn't reserved for the winners, where we can still compete, but where we must accept a price reduction that is far, far more moderate than the reduction the winners received. And on this point, I can say we are highly pleased with how the negotiations turned out. It came in significantly ahead of the worst-case scenario, in which we had said the worst case would be a price cut of roughly 30%. We are significantly better than that. And finally, I can only share so much, but what I will say is that in China, of course, next year we will see the full-blown VBP effect, right? We are confident — and I'll repeat what I said following the Q2 call — that across a 2 years' time period, so from 2020 to 2021, the base business in China will also return to growth. I'm, let's say, not courageous enough to promise you big growth for 2021, because there, as I mentioned, we will see the VBP effect. But across a 2-year period of time, the China-based business will return to growth.

Simon Baker

analyst
#39

There are two questions about Healthcare and one about Performance Materials. To start with Healthcare: when we look at how Mavenclad's TRx has been trending, it seems stronger now than it was prior to the pandemic, so I'm wondering if you could help us understand that. Is it catch-up, a change in access, or a shift in marketing? I'd just like your thoughts on why the performance clearly looks better than it did before the lockdowns. Then, coming back to bintrafusp, I fully appreciate that you can't and won't talk about any of the data. But presumably, the interim analysis — at least several of them — was prespecified in the study protocol. I'd like to ask, Marcus, if you could shed a little more light on what you meant by a multiple; and then last — two really fast PM questions. Would it be reasonable to think the normal depreciation and amortization expense in Q3 is a good run rate after Versum? And, also on Versum, can you verify that the acquisition growth effect has now been lapped, meaning Versum's acquisition impact on growth will be basically 0?

Marcus Kuhnert

executive
#40

Yes. That's a lot of questions. I'll do my best to get through them. Let me begin with the PM question. I'd say the Q3 depreciation and amortization rate for PM gives you a dependable run rate to use going forward. Nothing in the third quarter looks troubling to me. The PPA effects are completely reflected in it, so I consider that a reasonable assumption. Regarding Q4, you should figure that starting in the fourth quarter, the Versum business will begin adding to our organic growth. In other words, we've had three quarters counted as a portfolio effect, and Q4 will be organic. As for Mavenclad, honestly, that one isn't simple. Several effects are combining. Above all, COVID-19 hit Mavenclad at a really unfortunate moment—right in the middle of its ramp-up—and that has set us back somewhat. We're recovering now. I'd say it's fairly natural that we're seeing continued demand momentum during a launch that was still ramping, right? So there aren't necessarily any unusual factors behind the fact that our sales level now already surpasses where it stood before COVID-19. Because we have—I believe there were a lot of worries about how Mavenclad affects the immune system. At the same time, they're seeing some recommendations come out as well, indicating that the immune system recovers fairly quickly. I think the primary reason is really that we're simply further along in the launch, since more time has passed. On the other hand, we still see some sectors holding us back, because, for instance, the high-efficacy market remains depressed. We're gaining share, even though growth in the high-efficacy market — or rather where that market stands in terms of growth — has not yet come back to where it was before COVID, and that is holding us back somewhat as well. And should we witness some kind of recovery there, that ought to give another lift to Mavenclad's continued ramp-up as well. Let me add one more item that came up prominently in our quarterly review meetings. We were shown an interesting presentation indicating a very strong correlation linking patient mobility with how the high-efficacy market develops. What that means is that during lockdown periods, or whenever travel is restricted for people, the high-efficacy market takes a hit, right? So, let's say — let's hope the situation we're now seeing normalizes, or that an effective vaccination arrives soon. Should mobility rise, the high-efficacy market will rise too, and beyond that, Mavenclad sales; does that answer your question, Simon?

Simon Baker

analyst
#41

And one last thing about the bintrafusp interim — I was wondering whether you might, that would be great.

Marcus Kuhnert

executive
#42

Yeah. Yeah. So, like I mentioned, there's no standard practice that there are multiple interim analyses, though it could happen. And like I said, I can't say anything more, right? I think I've been clear. We can't provide further details on that.

Emily Field

analyst
#43

Let me just ask a question about Bavencio. I realize you addressed some of the launch figures for first-line bladder a few questions earlier. But looking ahead to 2021, the consensus for 2021 suggests a meaningful step-up in growth, basically doubling compared with the prior year. So is that something, given how you see the launch trajectory right now, that you believe can be delivered? Or put differently, could you perhaps share any figures on how large that overall market is in first-line bladder?

Marcus Kuhnert

executive
#44

So I'd say it's inherent to any launch we see, particularly in the earlier stage, to have a fairly strong ramp; so you can definitely assume Bavencio sales will accelerate further into 2021. The reason I believe we are — we have by now more or less reached peak sales in MCC, and frankly I don't expect much from bladder second line. Renal is somewhat flat in the U.S; and growing quite nicely outside; so the bulk of the growth in 2021, and certainly a further acceleration, will come from first-line bladder. The second question was market size, right, or the market's potential; so I can only answer that, let's say, in terms of patient numbers. And here — is this slide available? Emily, if you would just turn to Slide #38 — sorry, that was in the R&D update call. Now it highlights how many patients are actually eligible for Bavencio first-line bladder; so we begin with newly diagnosed metastatic UC cases, where we had roughly 20,000 patients in the U.S., roughly 30,000 in Europe and roughly 9,000 to 10,000 in Japan. If we assume 85% of those patients are platinum eligible, we arrive at 17,000 in the U.S., 25,000 in Europe and 8,000 in Japan. And then we have, let's say, also a portion of that who can take carboplatin or first-line treatment, and that brings the number down to roughly 8,500 patients in the United States, 21,000 in Europe and 7,000 in Japan. And then approximately 70% of those, we assume, will show a complete or partial response or a stable disease, which means they are ultimately then eligible for a maintenance therapy and for our Bavencio first-line bladder. So that is, let's say, the indication I can give you based on the patient data available. And of course, keep in mind, Emily, we have by now received approval in the United States; we also expect approval, or we are aiming for approval, in all the bigger jurisdictions. That means in Europe and in Japan as well in the second — sorry, in the first half of 2021; and please keep in mind, while we have not received a milestone payment for the U.S. Regarding bladder, since we already secured the second-line approval 2 years — 3 years ago, which opened the door to possible authorizations in Europe and Japan, a milestone payment would become due to us. That's a item worth keeping on your radar for next year.

Emily Field

analyst
#45

Would that be about the same size as the milestone before it?

Marcus Kuhnert

executive
#46

Yeah. Yeah. Every one of the milestones carries equal value. What varies is just the region. So Europe and North America come in at twice what Japan gets; but I believe you've already worked that out.

Krishna Arikatla

analyst
#47

I've got a couple, please. Marcus, regarding the General Medicine portfolio, a broader question there; that franchise isn't weighing on the overall Healthcare growth rate. How should we frame your priorities for that franchise? Are you considering running it for cash, or should we think about divestitures there, selling any of those products and redeploying those resources elsewhere in Healthcare? That's the first one. The second one, I realize you can't say much about bintrafusp, but I'll give it a try anyway. You said that both GSK and Merck are blinded to the data. Will the data stay blinded for the 2 companies until the study is completely finished, please? And if that's the case, on what basis would any potential milestones be paid?

Marcus Kuhnert

executive
#48

Thanks, KC. Regarding your first question, General Medicine has served as a key engine of growth for our Healthcare portfolio over the years, and it has also contributed solidly to growth at the group level; we truly don't anticipate that changing dramatically as we move forward. In fact, we need to manage the VBP impact, especially next year, when we face, for example, difficult comparables against a 2020 that was more or less unaffected; so that will be, shall we say, something of a challenge for — China, clearly, but also for the entire General Medicines portfolio, which we expect to be stable in 2021. That said, due to that effect, we then definitely expect a return to mid- to high-single-digit growth after 2021. Meanwhile, General Medicine isn't, I'd say, the area our group favors most when considering possible M&A deals. Still, I wouldn't — or can't completely — exclude that possibility. Regarding portfolio management, this is the standard matter; we review our portfolio periodically and assess whether these are, so to speak, businesses where ultimately we aren't the best strategic owner, on one hand. And naturally, whether there are areas — particularly strong growth areas — that we wish to reinforce. But I also want to be clear about where we're putting investment, particularly in M&A — those are the big 3. Obviously, in Healthcare, our new product pipeline is more of an organic or internal investment into our pipeline and its further development, but Process Solutions and Semiconductor Solutions are, I'd say, the priority areas for the next M&A move. On your second question about bintra: you asked, so bintra will stay blinded until 2023. What's the basis for potential milestones? First of all, yes, the data will remain blinded until the study is complete. As of now, the anticipated primary completion date falls in April 2023, as you're aware, and as we mentioned before, and it hinges on events. We'll only share the analysis from that trial after it finishes, and only once the complete data set for the dual primary endpoints has been gathered and examined — those endpoints, as you know, were revised in March to PFS and OS. So the development milestones are, again, linked to data from the lung cancer program, and that's everything I'm able to say.

Florent Cespedes

analyst
#49

Just a couple of quick things from me. First, regarding Healthcare — for 2021, which milestone would you consider the next most important, in your view? Then my second question — that one's about the research side. And the second question concerns Research Solution. Could you give us more color on whether this Q3 performance is essentially a one-off? And whether Q4 will be somewhat more depressed? Or should we expect somewhat more, let's say, dynamic demand in Q4 as well, in the fourth — early 2021? So just to get a sense of the shape of the trend in this business.

Marcus Kuhnert

executive
#50

Chris, would you like to begin with the research question?

Christos Ross

executive
#51

Of course, Marcus. Happy to. Thanks for asking. So yes, Research Solutions saw exceptional growth in Q3 — exceptionally strong — and we figure the net impact of the COVID-19 piece of that growth accounts for roughly 60% of Q3's growth; breaking it down, half of that growth comes from underlying COVID demand, and the other half comes from work actually being pulled in from Q4. And 2 other factors that partly offset each other: we saw a pretty significant catch-up effect from Q2. As you saw earlier, we had a very deep decline in Q2 and a very significant uptick in Q3. So that catch-up effect had an impact on Q3. And we should also be reminded, in the balance view, that academic labs aren't fully operational yet. So we've seen global activity trending in the right direction, but certainly still far from normal. So although Q3 was exceptional, there are some mitigating factors here in Q4 and beyond.

Marcus Kuhnert

executive
#52

Alright, thank you, Chris. I'll take the second question, which concerns Healthcare. Florent, you mentioned milestones, and I'm not entirely certain what you mean by that term. My guess is you're referring to the news flow for 2021. But to restate the impact once more: there are 2 milestone payments, which I just mentioned, tied to possible approvals for first-line bladder in Europe and in Japan. As I just outlined regarding the news flow side — this appears on Slide #42 of the presentation — I can also quickly share the key messages with you now. So for tepotinib METex14, an FDA approval is anticipated in the first quarter of 2021. And as you know, Japan has already granted approval. Over the medium term, we intend to pursue all jurisdictions. For first-line bladder, as already stated, approval is expected from the EMA and the Japanese MHLW during the first half of 2021; on Bavencio lung, our lung study, we anticipate having in-house data available in the second quarter, with the data readout then completed in the second half of 2021. And for bintrafusp, importantly, the second-line biliary tract data readout comes in Q1 2021. Then, in the second half of the year, the regulatory submission is expected, subject at that point to discussions or completion of discussions with the health authorities. We also have our M5049 TLR7/8 antagonist, our antibody against corona. And there, we anticipate seeing first results in the second quarter of 2021. So that is the news flow we expect for next year.

Constantin Fest

executive
#53

I appreciate everyone taking the time to ask questions on today's call. With that, I'll pass things over to Marcus, who has a few closing remarks. Thanks.

Marcus Kuhnert

executive
#54

Yes. Thank you, Constantin, and I also appreciate all of you for the strong and ongoing interest you've shown in Merck. Let me give you a summary. All in all, the third quarter proved very strong, and I believe it offers yet another demonstration that our strategy is being executed successfully. I can assure you that we will stay focused on tackling the challenges we currently confront in light of the pandemic, while at the same time making the most of the new possibilities that emerge; that being said, we will come back to you once more with our Q4 results in March. And I look forward to meeting many of you at the upcoming roadshow and conferences, this time, unfortunately, once again in a virtual setup, but I am also really looking forward to one or another personal meeting again. Let's hope that will work out next year. Thank you very much, and goodbye.

Operator

operator
#55

Thank you all for being here, ladies and gentlemen. That brings this call to a close. You're free to disconnect now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Merck KGaA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Merck KGaA earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck KGaA or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.